


Abstract

The present invention relates to heterocyclic derivatives of formula (I)



wherein

R represents halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;

R₁ represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R₁ represents a 4, 5 or 6 membered heterocyclic group, wherein said 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH₂)_pR₆, wherein p is zero or an integer from 1 to 4 and R₆ is selected from:

halogen,

C₁₋₄alkoxy,

C₁₋₄alkyl,

C₃₋₇cycloalkyl,

C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy,

hydroxy,

cyano,

nitro,

trifluoromethyl,

carboxy,

NH(C₁₋₄ alkyl),

N(C₁₋₄ alkyl)₂

NH(C₃₋₇ cycloalkyl),
N(C₁₋₄ alkyl)(C₃₋₇ cycloalkyl);
NH(C₁₋₄alkylOC₁₋₄alkoxy),
OC(O)NR₇R₈ ,
NR₈C(O) R₇ or
C(O)NR₇R₈;

R₂ represents hydrogen, or C₁₋₄ alkyl ;

R₃ and R₄ independently represent hydrogen, C₁₋₄ alkyl or R₃ together with

R₄ represents C₃₋₇ cycloalkyl;

R₅ represents trifluoromethyl, S(O)_qC₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ alkoxy,
trifluoromethoxy, halogen or cyano;

R₇ and R₈ independently represent hydrogen, C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

L is a single or a double bond;

n is an integer from 1 to 3;

m is zero or an integer from 1 to 3;

q is zero or an integer from 1 to 2;

provided that

a) when L is a double bond, R₁ is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;

b) the group R₁ is linked to the carbon atom shown as * via a carbon atom;
and

c) when the heteroatom contained in the group R₁ is substituted, p is not zero;

and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.